Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice
- PMID: 22873622
- DOI: 10.1007/BF03265491
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice
Similar articles
-
Sorafenib in hepatocellular carcinoma.Br J Hosp Med (Lond). 2010 Aug;71(8):451-6. doi: 10.12968/hmed.2010.71.8.77669. Br J Hosp Med (Lond). 2010. PMID: 20852487 Review.
-
Sorafenib, a systemic therapy for hepatocellular carcinoma.Ann Hepatol. 2008 Jan-Mar;7(1):46-51. Ann Hepatol. 2008. PMID: 18376365 Review.
-
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.Hepatology. 2010 Sep;52(3):1171-2. doi: 10.1002/hep.23702. Hepatology. 2010. PMID: 20812364 No abstract available.
-
Target therapy for hepatocellular carcinoma: is sorafenib for everybody?J Clin Gastroenterol. 2009 May-Jun;43(5):389-90. doi: 10.1097/MCG.0b013e31819eb9a6. J Clin Gastroenterol. 2009. PMID: 19564813 No abstract available.
-
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.Invest New Drugs. 2012 Aug;30(4):1768-72. doi: 10.1007/s10637-011-9707-4. Epub 2011 Jul 1. Invest New Drugs. 2012. PMID: 21720741 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical